Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

被引：0
|
作者：
ZH Israili
机构：
[1] Emory University School of Medicine,
来源：
Journal of Human Hypertension | 2000年 / 14卷
关键词：
angiotensin receptor blockers; candesartan; eprosartan; irbesartan; losartan; telmisartan; valsartan; pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Angiotensin II receptor blockers (ARBs) represent a new class of effective and well tolerated orally active antihypertensive agents. Recent clinical trials have shown the added benefits of ARBs in hypertensive patients (reduction in left ventricular hypertrophy, improvement in diastolic function, decrease in ventricular arrhythmias, reduction in microalbuminuria, and improvement in renal function), and cardioprotective effect in patients with heart failure. Several large long-term studies are in progress to assess the beneficial effects of ARBs on cardiac hypertrophy, renal function, and cardiovascular and cerebrovascular morbidity and mortality in hypertensive patients with or without diabetes mellitus, and the value of these drugs in patients with heart disease and diabetic nephropathy.
引用
收藏
页码：S73 / S86
相关论文
共 50 条
  • [21] Transcend aftermath: Angiotensin ii type 1 receptor antagonists (angiotensin receptor blockers) at the clinical crossroad
    Volpe M.
    High Blood Pressure & Cardiovascular Prevention, 2009, 16 (1) : 1 - 6
  • [22] Radioligands for the Angiotensin II Subtype 1 (AT1) Receptor
    Mathews, William B.
    Szabo, Zsolt
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2010, 10 (16) : 1585 - 1599
  • [23] Angiotensin II type 1 receptor blockers
    Burnier, M
    CIRCULATION, 2001, 103 (06) : 904 - 912
  • [24] ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS
    Luan, L.
    Hu, H.
    Li, S. S.
    VALUE IN HEALTH, 2018, 21 : S35 - S35
  • [25] Angiotensin II receptor blockers in the therapeutic choice for patients with hypertension
    Georgiev, B.
    Gotcheva, N.
    Baytcheva, V.
    Gotchev, D.
    Ivanov, I.
    Hazan, M.
    JOURNAL OF HYPERTENSION, 2008, 26 : S454 - S454
  • [26] Chronic production of angiotensin IV in the brain leads to hypertension that is reversible with an angiotensin II AT1 receptor antagonist
    Lochard, N
    Thibault, G
    Silversides, DW
    Touyz, RM
    Reudelhuber, TL
    CIRCULATION RESEARCH, 2004, 94 (11) : 1451 - 1457
  • [27] Combination ACE inhibitors and angiotensin II receptor blockers for hypertension
    Finnegan, PM
    Gleason, BL
    ANNALS OF PHARMACOTHERAPY, 2003, 37 (06) : 886 - 889
  • [28] ACE inhibition and AT1 receptor blockers:: efficacy and duration in hypertension
    Meredith, PA
    HEART, 2000, 84 : I39 - I41
  • [29] Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension
    Fu, MLX
    Herlitz, H
    Schulze, W
    Wallukat, G
    Micke, P
    Eftekhari, P
    Sjögren, KG
    Hjalmarson, Å
    Müller-Esterl, W
    Hoebeke, J
    JOURNAL OF HYPERTENSION, 2000, 18 (07) : 945 - 953
  • [30] Angiotensin II type 1 (AT1) receptor antagonists in the treatment of hypertension after renal transplantation
    Holgado, R
    Anaya, F
    Del Castillo, D
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2001, 16 : 117 - 120
12345